Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14957694 | 1.00 | ESR1 (0.54) | ESR1ESR2DRD3SLC6A9GRIN2B | |
| SCHEMBL14957695 | 1.00 | ESR1 (0.54) | ESR1ESR2DRD3SLC6A9GRIN2B | |
| SCHEMBL3105867 | 0.86 | ESR1 (0.55) | ESR1ESR2DRD3SLC6A9CYP26A1 | |
| SCHEMBL16659174 | 0.85 | SLC6A9 (0.43) | ESR1ESR2SLC6A9GRIN2B | |
| SCHEMBL6823363 | 0.82 | HTR6 (0.50) | SLC6A9GRIN2B | |
| SCHEMBL3100512 | 0.82 | SLC6A9 (0.56) | ESR1ESR2DRD3SLC6A9DRD2 | |
| SCHEMBL16652211 | 0.81 | SLC6A9 (0.58) | ESR1ESR2DRD3SLC6A9 | |
| SCHEMBL20958658 | 0.81 | SLC6A9 (0.58) | ESR1ESR2DRD3SLC6A9 | |
| SCHEMBL20958655 | 0.81 | SLC6A9 (0.58) | ESR1ESR2DRD3SLC6A9 | |
| SCHEMBL10436404 | 0.81 | ESR1 (0.54) | ESR1ESR2DRD3GRIN2BCYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| EP-3057958-B1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-05-01 | — | — | EP | disclosed |
| EP-3057958-B1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-05-01 | — | — | EP | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-9586942-B2 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586942-B2 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586942-B2 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| EP-3057958-A1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-20150111875-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111875-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015055771-A1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111875-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| US-8846741-B2 | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2780328-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-20130131132-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013072520-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | ESR1 4759/4885ESR2 4131/4885DRD3 896/4885 |
| US-20150111875-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | ESR1 4759/4885ESR2 4131/4885DRD3 896/4885 |
| US-20130131132-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, NMT1 | ESR1 4191/4885ESR2 2838/4885DRD3 1254/4885 |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | ESR1 4759/4885ESR2 4131/4885DRD3 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.